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Background: Ineffective induction of T cell mediated immunity in older individuals remains a persistent challenge
for vaccine development. Thus, there is a need for more efficient and sophisticated adjuvants that will complement
novel vaccine strategies for the elderly. To this end, we have investigated a previously optimized, combined
molecular adjuvant, CASAC (Combined Adjuvant for Synergistic Activation of Cellular immunity), incorporating two
complementary Toll-like receptor agonists, CpG and polyI:C, a class-II epitope, and interferon (IFN)-γ in aged mice.
Findings: In aged mice with typical features of immunosenescence, antigen specific CD8+ T cell responses were
stimulated after serial vaccinations with CASAC or Complete/Incomplete Freund’s Adjuvant (CFA/IFA) and a class I
epitope, deriving either from ovalbumin (SIINFEKL, SIL) or the melanoma-associated self-antigen, tyrosinase-related
protein-2 (SVYDFFVWL, SVL). Pentamer analysis revealed that aged, CASAC/SIL-vaccinated animals had substantially
higher frequencies of H-2Kb/SIL-specific CD8+ T cells compared to the CFA/IFA-vaccinated groups. Similarly, higher
frequencies of H-2Kb/SVL-pentamer+ and IFN-γ+ CD8+ T cells were detected in the aged, CASAC + SVL-vaccinated
mice than in their CFA/IFA-vaccinated counterparts. In both antigen settings, CASAC promoted significantly better
functional CD8+ T cell activity.
Conclusion: These studies demonstrate that functional CD8+ T cells, specific for both foreign and tumour-
associated self-antigens, can be effectively induced in aged immunosenescent mice using the novel multi-factorial
adjuvant CASAC.
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Introduction
The sequelae of immunosenescence in older individuals,
including increased morbidity and mortality from infec-
tion and malignancy, represent a critically important
public health problem [1]. As a consequence of accumu-
lated dysfunctions in the immune system during ageing,* Correspondence: linda.barber@kcl.ac.uk; farzin.farzaneh@kcl.ac.uk
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creativecommons.org/publicdomain/zero/1.0/vaccination of older individuals is less efficacious than in
the young [2, 3]. Previous attempts to increase vaccin-
ation efficacy by incorporating various adjuvants, includ-
ing alum, have shown only modest success [2]. Thus,
there is an unmet need for new vaccine strategies for the
elderly.
Immunosenescence is characterised by decline in both
adaptive and innate immune functions [4, 5]. Innate
immune responses are activated, mainly, by stimulation
of Toll-like receptors (TLRs) [6], the expression and
function of which declines with age [7]. Dendritic cells
(DCs) from both young and aged individuals exhibite distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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and are equally capable of direct and cross-presentation
of antigens to T cells in vitro [8], underscoring the likely
importance of TLR-induced DC activation in promoting
adaptive immunity. TLR stimulation is therefore a prom-
ising strategy to enhance vaccine efficacy in the elderly.
Combinations of TLR agonists may be especially effect-
ive, as demonstrated in animal models and clinical trials
[6, 9–13].
We previously showed that triggering of multiple
TLRs, using a combined adjuvant for synergistic activa-
tion of cellular immunity (CASAC), incorporating CpG,
polyI:C, interferon (IFN)-γ and MHC-class I and II pep-
tides, results in potent cytotoxic T cell-mediated immun-
ity in young mice [14]. Optimization of the adjuvant
formulation and investigation of mechanism of action
were also performed [14]. We now report the ability of
CASAC to improve vaccination-induced responses in
aged mice by promoting induction of antigen-specific
cellular immunity to both foreign and self tumour-
associated peptide antigens.
Methods
Animals and vaccination procedures
Young (6–8 weeks old) and aged (18–22 months old)
wild-type C57BL/6 female mice were purchased from
Harlan, UK. All animal procedures were performed ac-
cording to UK Home Office and institutional regulations.
CASAC vaccine comprised of an oil-in-water emulsion
consisting of Tween-80 and squalene (all Sigma, UK), as
previously described [14]. The tween/squalene mixture
was sonicated and mixed at a 1:1 ratio with PBS contain-
ing: 50 μg polyI:C (TLR3 agonist; Sigma), 25 μg CpG
1826 (TLR9 agonist; Eurofins, UK), 100 ng mouse re-
combinant IFN-γ (Peprotech, UK), 100 μg ISQAVHAA-
HAEINEAGR (ovalbumin (OVA)-derived MHC-class II
(H-2IAb)-restricted peptide) and 100 μg SIINFEKL (SIL;
OVA-derived MHC-class I (H-2Kb)-restricted peptide)
or SVYDFFVWL (SVL; tyrosinase related protein (TRP)-
2-derived MHC-class I (H-2Kb)-restricted peptide; all
PPR, UK). Alternatively, 100 μg of SIL or SVL was emul-
sified with Complete Freund’s Adjuvant (CFA) for the
first vaccination, and Incomplete FA (IFA; all Sigma) for
subsequent vaccinations at a 1:1 (vol/vol) ratio. All vac-
cine formulations were administered intradermally on
days 0, 10, 20 and 30 (±1 day) in 100 μL final volume
(50 μL/flank).
Flow cytometric analysis
Cell enumeration was performed in whole blood samples
using Flow-Count™ beads (Beckman Coulter, UK) ac-
cording to manufacturer’s instructions. After red blood
cell lysis, mononuclear cells were stained with anti-CD3/
eFluor 450, anti-CD4/FITC and anti-CD8a/PerCP-Cy5.5monoclonal antibodies (mAb) (all eBioscience, USA).
Expression of PD-1, KLRG1 and LAG-3 was assessed in
whole blood samples after staining with anti-CD3/eFluor
450, anti-CD8a/PerCP-Cy5.5, anti-PD-1/FITC, KLRG-1/
APC and anti-LAG-3/PE mAbs (all eBioscience). Penta-
mer analysis was performed as previously described [14],
using H-2Kb/SIINFEKL or H-2Kb/SVYDFFVWL Pro5
pentamer/PE (ProImmune, UK).
To assess peptide-induced intracellular accumulation
of IFN-γ by CD8+ T cells, splenocytes were stimulated
with 1 μg/mL SVL peptide, 0.5 μg/mL co-stimulatory
anti-CD28 antibody (eBioscience) in the presence of
GolgiPlug (BD Biosciences, Belgium) for 5 h prior to fix-
ation, permeabilization, and staining with anti-CD3/eFluor
450, anti-CD8a/PerCp-Cy5.5 and anti-IFN-γ/PE mAbs
(eBioscience).
Samples were analysed using a FACSCantoII (BD
Biosciences) and FACSDiva (BD Biosciences) or FlowJo
(Treestar, OR) software.
In vivo cytotoxicity assay
The in vivo cytotoxicity assay was performed as previ-
ously described [14].
Statistical analysis
The Mann-Whitney U test (GraphPad Prism, USA) was
used to compare distributions, with p < 0.05 considered
significant.
Results and discussion
Previous studies have shown that immunosenescence as-
sociated with increasing age is especially pronounced
within the T cell compartment [15–17]. Consistent with
these reports, aged C57BL/6 mice used in our study had
significantly lower CD4+ (median 270 cells/μL blood) and
CD8+ (median 189 cells/μL of blood) T cell numbers,
compared to young mice (1527 CD4+/μL blood; p <
0.0001 and 1067 CD8+/μL blood; p < 0.0001) (Fig. 1a).
CD4+ and CD8+ T cell percentages were also decreased
significantly in aged (median 10.8 and 6.2 % of all
lymphocytes, respectively), compared to young mice
(30.00 %; p < 0.0001 and 20.90 %; p < 0.0001, respectively)
(Fig. 1b). Expression of PD-1, KLRG-1 and LAG-3, indica-
tive of T cell exhaustion and anergy [18, 19], was signifi-
cantly elevated on CD8+ T cells in aged mice (Fig. 1c)
compared to young counterparts.
CASAC enhances responses to a foreign antigenic CD8+ T
cell epitope in aged mice
CASAC was previously shown to effectively promote T
cell immunity to the foreign antigen OVA in young mice
[14]. We therefore investigated whether CASAC augments
responses to the immunogenic OVA peptide SIL [20] in
aged mice, compared to CFA/IFA as a conventional
Fig. 1 Age-associated differences in peripheral blood T cell subsets. The absolute numbers (a) and percentages (b) of CD4+ and CD8+ T cells
were determined in blood samples from young (open circles) and aged (filled circles) C57BL/6 mice by flow cytometric analysis using counting beads.
c Expression of PD-1, KLRG-1 and LAG-3 on CD8+ T cells in young and aged mice. Each symbol represents an individual mouse and the median is
indicated by a horizontal line. Data is pooled from 2 independent experiments. The Mann-Whitney U test was used to compare distributions
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cination protocol [14], young and aged C57BL/6 mice
were vaccinated twice at a 10-day interval with SIL, com-
bined either with CFA/IFA or CASAC. The distribution of
percentages of H-2Kb/SIL-pentamer+ CD8+ T cells was
significantly higher (p = 0.0003) in the CASAC-vaccinated
group (median 14.55 %), compared to CFA/IFA vaccina-
tions (0.80 %). As shown previously [14], distribution of
H-2Kb/SIL-pentamer+ CD8+ T cell frequencies was also
found to be significantly higher (p = 0.0002) in young mice
vaccinated with CASAC (median 13.80 %), compared to
their CFA/IFA-treated counterparts (0.29 %). Of im-
portance, the H-2Kb/SIL-pentamer+ CD8+ T cell fre-
quencies induced by CASAC vaccinations in both
young and aged mice were similar. Although similar
percentages were induced in both CASAC-vaccinatedFig. 2 CASAC enhances CD8+ T cell responses to a foreign antigenic epito
C57BL/6 mice were vaccinated twice with the SIL peptide from OVA in com
percentage of H-2Kb/SIL-pentamer + CD8+ T cells was assessed after stainin
numbers of H-2Kb/SIL-pentamer + CD8+ T cells were enumerated by flow cyt
and CFSEhigh-SVL-loaded splenocytes, as antigen-specific and control targets,
immunised and control mice. Eighteen hours later, all spleens were harve
cytometry. The percent target lysis was calculated with the following formula:
animal)/(number of CFSElow/ number of CSFEhigh in unimmunised animal)] ×
indicated by a horizontal line. Data is pooled from 2 independent experimentcohorts, the absolute numbers of SIL-specific CD8+ T
cells (Fig. 2b) showed a significantly lower (p = 0.0033)
distribution in aged mice (median 22.30) compared to
their young counterparts (396.3). This was due to the
lower total numbers of CD8+ T cells in aged mice
(Fig. 1a). The function of SIL-specific T cells was
assessed by performing in vivo cytolytic assays. Aged
mice vaccinated with CASAC showed higher distribu-
tion of antigen-specific cytolytic activity (median
88.5 %; Fig. 2c) compared to the CFA/IFA-vaccinated
mice (16.8 %; p = 0.0106). Similar outcomes were
observed in the young groups (98.0 and 58.1 % for
CASAC and CFA/IFA vaccinated groups, respectively;
p = 0.0238). These results show that CASAC effectively
induced CD8+ T cell mediated immunity to a foreign
antigen in both aged and young mice.pe in aged mice. Young (open symbols) and aged (filled symbols)
bination with either CFA/IFA (circles) or CASAC (triangles). a The
g of peripheral blood samples with H-2Kb/SIL-pentamer. b Absolute
ometry. c % Lysis of target cells was assessed using CFSElow–SIL-loaded
respectively. Both populations were mixed and injected iv into the
sted and splenocytes were analysed for their CFSE content by flow
% lysis = 1 – [(number of CFSElow/ number of CSFEhigh in immunised
100. Each symbol represents an individual mouse and the median is
s. The Mann-Whitney U test was used to compare distributions
Fig. 3 CASAC enhances CD8+ T cell responses to a tumour-associated epitope in aged mice. Aged C57BL/6 mice were vaccinated four times with
the SVL peptide from TRP-2 in combination with either CFA/IFA (circles) or CASAC (triangles). a The percentage of H-2Kb/SVL-pentamer + CD8+ T
cells was assessed after staining with H-2Kb/SVL-pentamer. b % Lysis of target cells was assessed (as explained in the legend to Fig. 2c) using CFSElow–
SVL-loaded and CFSEhigh-SIL-loaded splenocytes as antigen-specific and control targets, respectively. c Production and intracellular accumulation of
IFN-γ in CD8+ T cells in response to the vaccinated peptide was assessed using flow cytometry, after in vitro SVL peptide stimulation of splenocytes for
5 h. Each symbol represents an individual mouse and the median is indicated by a horizontal line. Data is pooled from 2 independent experiments.
The Mann–Whitney U test was used to compare distributions
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cell epitope in the aged mice
The need for efficient vaccine adjuvants applies not only
to infectious disease but also to cancer, a disease with
increasing age-associated incidence [22]. It is therefore
imperative that new adjuvants incorporated in anti-
cancer vaccines are assessed for efficacy in aged immu-
nosenescent individuals.
We have previously shown that immune tolerance to
the melanoma-associated self-antigen TRP-2 can be
overcome by vaccination of young mice with the TRP-2
peptide SVL combined with CASAC [14]. Functional
SVL-specific CD8+ T cells were detected after two rounds
of vaccinations; however, responses were of variable mag-
nitude and required vaccination with the higher peptide
dose of 400 μg. We therefore performed further
optimization studies in young mice and found four rounds
of vaccination, using 100 μg SVL peptide with CASAC,
consistently induced higher frequencies of SVL-specific
CD8+ T cells (data not shown). All studies with aged mice
were performed with four rounds of vaccination using
100 μg SVL peptide in combination with either CASAC or
CFA/IFA. Distribution of SVL-specific CD8+ T cell fre-
quencies was higher in the SVL + CASAC-vaccinated
group (median 2.5 %) compared to the SVL + CFA/IFA-
vaccinated group (0.7 %), although the difference did not
reach statistical significance (p = 0.0673; Fig. 3a). In vivo
cytotoxicity studies (Fig. 3b) showed that lysis of SVL-
loaded splenocytes was significantly higher in SVL +
CASAC-vaccinated (median 86.6 %) compared to SVL +
CFA/IFA-vaccinated aged mice (median 19.7 %; p =
0.0028). Additionally, distribution of IFN-γ+CD8+ T cell
frequencies after in vitro SVL peptide stimulation was sig-
nificantly higher in the SVL + CASAC-vaccinated mice(median 8.9 %; Fig. 3c) compared to CFA/IFA-vaccinated
mice (1.2 %; p = 0.0028). Thus, vaccination of aged mice
with the tumour-associated SVL peptide and CASAC in-
duced antigen-specific CD8+ T cells that had considerably
better functional activity than CD8+ T cells induced by
SVL +CFA/IFA-vaccination.
In conclusion, we have demonstrated that our com-
bined molecular adjuvant CASAC effectively promotes
functional antigen-specific CD8+ T cell responses to
vaccination with peptides in aged mice, despite their
immunosenescent phenotype. CASAC improved re-
sponses in aged mice not only to a highly immunogenic
foreign antigen, but also to the tumour-associated self-
antigen TRP-2 whose immunogenicity is being evaluated
in clinical trials [23]. Restoration of response to vaccin-
ation in immunosenescent aged mice by CASAC likely
reflects the benefits of multiple TLR triggering on DC
function [14, 24, 25] and provision of IFN-γ could sub-
stitute for lack of IFN-γ from CD8+ memory cells dur-
ing the early phase of immune response. Since CASAC
comprises a combination of agents that individually are
approved for human use, our findings suggest that a
CASAC-based vaccination strategy may be amenable to
rapid clinical translation, particularly against chronically
experienced antigens such as persistent infections or
tumour-associated antigens in older people.
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